GlobalData on MSN3d
Rigel enrols first subject in Phase I sickle cell disease therapy trialRigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...
Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback